000027364 000__ 01242cam\a2200349\i\4500
000027364 001__ 27364
000027364 003__ SzGeWIPO
000027364 005__ 20210318105100.0
000027364 008__ 971009s1997\\\\enk\\\\\r\\\\u000\0\eng\d
000027364 035__ $$a(wipo)(CD )97-1354
000027364 035__ $$a(OCoLC)1161450991
000027364 040__ $$aSzGeWIPO$$beng$$erda$$cSzGeWIPO$$dCaBNVSL
000027364 050_4 $$aK3925.B56$$bA152
000027364 08204 $$a344.095$$221
000027364 084__ $$aGB 110 
000027364 1001_ $$aPorter & Arnold.,$$eauthor.
000027364 24510 $$aTransparency of clinical trial data :$$bCurrent state of play.
000027364 264_1 $$aOxon :$$bLawtext Publishing,$$c1997.
000027364 300__ $$a1 volume ([4] pages) ;$$c[28] cm.
000027364 336__ $$atext$$btxt$$2rdacontent
000027364 337__ $$aunmediated$$bn$$2rdamedia
000027364 338__ $$avolume$$bnc$$2rdacarrier
000027364 4901_ $$aBio-Science Law Review,$$x1365-8867 ;$$vGB 110 2014 Vol. 13 Issue No. 6, pages 204-207
000027364 650_0 $$aBiotechnology.
000027364 650_4 $$aIntellectual property rights
000027364 650_4 $$aBiotechnology
000027364 650_6 $$aGénie génétique$$xDroit.
000027364 830_0 $$aBio-Science Law Review ;$$vGB 110 2014 Vol. 13 Issue No. 6, pages 204-207.
000027364 903__ $$aBIO-SCIENCE LAW REVIEW
000027364 942__ $$cART$$jGB 110 2014 Vol. 13 Issue No. 6$$2ddc
000027364 952__ $$w2014-06-17$$p2014-0125$$u41851$$bMAIN$$10$$kGB 110 $$v2014-06-17$$zTagged$$71$$cLibrary
000027364 980__ $$aBIB
000027364 999__ $$c29788$$d29788